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Abstract
Background: Up to fifty percent of microbiologically cured tuberculosis (TB) patients may be left with permanent,
moderate or severe pulmonary function impairment. Very few studies have systematically examined pulmonary
outcomes in patients to understand the pathophysiologic basis and long-term socio-economic consequences of
this injury. The planned multi-country, multi-centre observational TB cohort study, aims to advance the understanding
of the clinical, microbiological, immunological and socio-economic risk factors affecting long-term outcome of
pulmonary TB. It will also determine the occurrence of reversible and irreversible socio-economic consequences to
patients, their households and the health sector related to pulmonary TB disease and its treatment.
Methods: We will enrol up to 1.600 patients with drug sensitive and multidrug-resistant pulmonary TB who are treated
according to the local standard of care by the respective National TB Program. Recruitment is taking place at the
time of TB diagnosis at four African study clinics located in The Gambia, Mozambique, South Africa and Tanzania.
The primary outcome is the proportion of TB patients with severe lung impairment measured by spirometry at 24
months after TB treatment initiation. Biological samples, including sputum, urine and blood, for studying host- and
pathogenic risk factors will be collected longitudinally and examined in a nested case-control fashion. A standardized
quality of life questionnaire will be used together with a novel version of WHO’s generic patient cost instrument which
has been adapted for the longitudinal study design.
Discussion: This study is an integral part of an overall strategy to fill a knowledge gap needed to improve TB treatment
outcomes globally. The main scientific goal is to identify the major pathogenic mechanisms associated with poor TB
treatment outcomes, so that such pathways can be interrupted to avert long term TB sequelae. National as well as
supra-national stakeholders and decision makers have been integrated early in the study planning process to
inform future treatment guidelines and national health policies.
Trial registration: ClinicalTrials.gov: NCT03251196, August 16, 2017.
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Background
Tuberculosis (TB) remains one of the world’s deadliest
communicable diseases. In 2016, an estimated 10.4
million people developed TB and 1.3 million died from
the disease [1]. TB related morbidity and mortality re-
main particularly high in African countries, mainly due
to the impact of HIV, sustained poverty and food inse-
curity as well as due to treatment challenges including
the rise in drug-resistant TB [2].
For the past 40 years, treatment success in tuberculosis
has been defined as the eradication of active infection
whilst preventing resistance and recurrence, achieved
through multidrug antimicrobial treatment. Current esti-
mates of the global TB disease burden include incidence
and prevalence of active TB, TB death rates, and
disability-adjusted years of life (DALY) lost due to active
TB, but do not consider DALYs lost due to long-term
disability due to TB sequelae or reduced longevity in
patients considered cured [3, 4]. However, accumulating
evidence indicates that permanent lung injury due to TB
is frequent and substantial. In one study in Papua New
Guinea, the mean FEV1 (the maximal volume of air
exhaled in the first second after a full inspiration), was
reduced to 64% of that of healthy controls at the time of
TB diagnosis [5]. FEV1 improved by 11% after 2 months
of TB treatment, but did not further improve subse-
quently. At the conclusion of successful anti-microbial
treatment, 27% of TB patients still had moderate or se-
vere impairment of pulmonary function. [5]. Another
study from India found severe and irreversible obstruct-
ive pulmonary ventilation defects in one-third of TB pa-
tients one year after completion of TB treatment [6]. A
literature review of South African studies showed that
lung function impairment and chest symptoms were
consistently associated with pulmonary TB [7]. In the
United States, studies demonstrated that even persons
cured from TB have considerably shortened life expect-
ancy [5, 6]. There is limited evidence on pulmonary
function impairment in African populations outside
South Africa and presently no estimates of the impact of
TB on life expectancy in African patients. Further, asso-
ciated risk factors contributing to permanent lung func-
tion impairment after TB are unknown.
Clinical, environmental and behavioural risk factors
The risk of developing TB is up to 30 times greater in
people living with HIV than among those without HIV
infection [8]. TB patients with advanced AIDS are at in-
creased risk of immune reconstitution inflammatory syn-
drome (IRIS) and death. The long-term effects of HIV
and antiretroviral treatment on lung function, however,
are not known. Diabetes mellitus is also recognized as a
TB risk factor and the African region is experiencing an
increasing prevalence of diabetes alongside other
non-communicable diseases [9–11]. However, little is
known about the potential impact of diabetes on
long-term TB outcomes. Other risk factors that can po-
tentially have long term effects include pre-existing pul-
monary conditions like Chronic Obstructive Pulmonary
Disease (COPD) and asthma, and associated risk factors
such as smoking, indoor air pollution and harmful alco-
hol use [12, 13]. Malnutrition is also an important risk
factor for TB [14], however, the association with seque-
lae after treatment has not been studied.
Host-immune response and associated risk factors
It is well known that host responses to Mycobacterium
tuberculosis (MTB) also contribute to lung pathology
through excessive induction of the inflammatory path-
way. However, whether the systemic host response be-
fore and after TB treatment initiation can be used to
predict pathology and treatment outcomes is largely un-
known. Blood and sputum-derived neutrophil activation
and inflammatory mediators will be examined in order
to elucidate the predominant pathway of lung inflamma-
tion in TB and inform on future host-adjunctive therapy
strategies. For example, polymorpho-nuclear neutro-
philic granulocytes have been associated with active tu-
berculosis and the failure to control the infection, and
likely contribute to exacerbated pathology and long term
sequelae and lung function loss [15–17]. Additionally,
there are very few studies that have assessed specific
host biomarkers in clinical research studies, such as the
T-cell activation marker-tuberculosis (TAM TB) assay
[18], which have shown a correlation with diagnosis and
treatment response in TB [19].
Pathogen diversity and microbial risk factors
There is increasing evidence that genomic diversity of
the MTB complex influences important patho-biological
properties, such as transmissibility and pathogenicity,
and affects host-immune responses and clinical mani-
festations [20, 21]. Moreover, microbial factors are rec-
ognized as important determinants of microbiologic
outcomes such as treatment failure or relapse. Baseline
drug resistance can affect the risk of new (acquired) re-
sistance and subsequent treatment failure. For some
drugs, such as rifampin, this effect can be profound
[22]. Sputum bacillary burden at baseline and culture
status after 2 months of treatment affect relapse risk
[23]. However, very little is known about the contribu-
tions of all these and other microbial factors, such as
strain genetic background or the presence of mixed in-
fections, on long-term pulmonary function outcomes.
Socio-economic determinants and costs of tuberculosis
Several previous studies have documented high patient
costs before patients are diagnosed and during TB
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treatment [24, 25], where patients may lose about half of
their household income due to TB. Loss of income and
direct expenses may result in poorer treatment out-
comes, including increased risk of TB infection and pro-
gression, the development of drug resistance and long
term pulmonary impairment. The WHO End TB Strat-
egy has included an microeconomic target, that no TB
patient or affected household should experience cata-
strophic expenditure or costs related to TB illness and
TB care [26], and a generic protocol for the measure-
ment of catastrophic costs due to TB has been devel-
oped [27]. Measuring catastrophic cost is a useful
indicator of equality in advancing towards universal
health coverage. Although patient costs during diagnosis
and TB treatment has been documented there is little
evidence on the costs and socioeconomic consequences
of TB after treatment has been completed and how they
are associated to different clinical TB outcomes. In
addition, the published literature contains surprisingly
little evidence about the costs to the health systems of
treating TB and TB sequelae, especially in Africa.
Study aim
TB Sequel project aims to: i) advance understanding of
the clinical, microbiological, immunological and socio-
economic risk factors affecting or predicting the long-
term pulmonary function outcome; ii) determine costs
on patient and health system level related to TB disease,
TB treatment and TB sequelae.
Methods/design
Study partners and setting
The TB Sequel cohort study is conducted by the TB Se-
quel consortium including a number of research institu-
tions based in Africa and Europe (Additional file 1). The
Division of Infectious Diseases and Tropical Medicine at
the University of Munich (LMU), Germany and The
AURUM Institute in Johannesburg, South Africa coord-
inate the project. The TB Sequel cohort study will re-
cruit TB patients in four African countries of which
three belong to high TB burden countries. In Johannesburg,
South Africa, the study is conducted by the University of
Witwatersrand (WITS) at the Clinical HIV Research Unit
(CHRU) located at the Helen Joseph Hospital that serves
an urban area with approximately one million inhabitants.
In Mbeya, Tanzania, the study takes place at the National
Institute of Medical Research - Mbeya Medical Research
Centre (NIMR-MMRC). The NIMR-MMRC is located
within the same premises of the Mbeya Zonal Referral
Hospital (MZRH), one of the four largest referral hospitals
in Tanzania, which serves a total population of about
500.000 inhabitants. In Maputo, Mozambique, the Insti-
tuto Nacional de Saúde (INS) is conducting the TB Sequel
cohort study at two research units, first located in
Mavalane Health Centre (City of Maputo) serving
approximately 620.000 inhabitants, and second, located in
Machava General Hospital (Province of Maputo) where
the majority of MDR-TB patients of Maputo are treated.
In The Gambia, this study is conducted by the Medical
Research Council (MRC) Unit The Gambia in the Greater
Banjul area, where two thirds of all TB patients diagnosed
in the country present. The Research Center Borstel
(FZB) in Germany is responsible for MTB isolates typing
and contributes to host responses studies including
training of African researchers. The socio-economic
sub-study is being led by the Health Economics and
Epidemiology Research Office (HE2RO) at WITS University
in South Africa in collaboration with the Department of
Public Health Sciences at Karolinska Institutet, Sweden and
WHO Geneva.
Study design
We will conduct a prospective, multi-country, multi-
centre, observational cohort study and recruit up to 1.600
pulmonary TB patients at the time of TB diagnosis who
will be followed during and after TB treatment. At
enrolment, TB diagnosis is based on sputum tested positive
for the presence of MTB either by Xpert MTB/RIF (or
Ultra) or culture methods (Fig. 1). At baseline and at de-
fined study visits (see Schedule of Events (SOE) Table 1)
clinical data, data on risk factors, information on comorbid-
ities, socio-economic data, as well as biological samples
(sputum, urine and blood) will be collected from all partici-
pants. This large cohort will therefore serve as a platform
for all nested research activities related to immunological,
microbiological and socio-economic studies as well as
future therapeutic interventions (Additional file 2).
Participant eligibility
For enrolment, each study participant must meet all of
the inclusion criteria and none of the exclusion criteria
summarized in Table 2.
Duration of study
Recruitment commenced in September 2017 and is
expected to continue until September 2019. Follow-up
will last for a minimum of 24months in all participants
to ensure that any loss in reported lung function will
have become chronic during follow-up [28]. Further, the
chronicity and final degree of long term costs and co-
morbidities resulting from TB disease or treatment shall
be confirmed by a follow up period of at least 24 months
length. End of study is expected in September 2021.
Primary outcome and study endpoints
The primary outcome is a proportion of TB patients
with severe pulmonary function impairment (restrictive,
obstructive or mixed ventilation impairment), measured
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by spirometry at 24 months from TB treatment initiation
and compared to national reference values. Long term
lung function impairment is considered a clinically
meaningful condition contributing to long term morbid-
ity and mortality in former TB patients.
Amongst secondary outcomes are: the proportion of
subjects with any impairment of pulmonary function as
well as severity and type of impairment at TB diagnosis
and 2, 6, 12 and 18months; proportion of subjects with li-
quid and solid MTB culture conversion at different time
points during or at the end of anti-TB treatment; the fre-
quency of all-cause hospitalization episodes and all-cause
mortality during follow-up of 24months; the proportion
of subjects with recurrent TB and; the proportion of sub-
jects suffering from ongoing non-pulmonary comorbidi-
ties which are related to TB disease and treatment at
different time points during 24months of follow-up.
Studies regarding host immunology- and pathogen-as-
sociated risk factors and markers are planned as explora-
tive, nested, case-control studies. Sample selection will
be based on specific outcomes and risk factors present
in the study participants.
Main outcomes studied in the context of socio-eco-
nomic research are the proportion of subjects incurring
catastrophic cost due to TB by the end of treatment;
changes in income within follow up period; and scales
for quality of life and general disability at treatment
start, end of treatment and at follow-up. The cost of
providing TB care and treatment, will be estimated from
the health provider perspective, for both drug sensitive
and drug resistant TB.
Sample size
We hypothesized that the prevalence of the primary endpoint
- severe lung impairment at 24months period of follow up
after TB diagnosis (conservative estimation based on a litera-
ture review) will be 15%. A sample size of 1.600 patients al-
lows the estimation of the primary end point in the total
cohort with a precision (half width of the 95% confidence
interval) of about 1.75%. In addition, the prevalence within
specific subgroups can be estimated adequately, e.g. with a
precision between 2.5 and 7.8% in subgroups with a propor-
tion of 50% (e.g. HIV) and 5% (e.g. diabetes) of the total co-
hort, respectively. Moreover, based on a pre-set alpha of 5%
(two-sided) the sample size allows the detection of risk factors
causing a duplication of the prevalence of severe lung impair-
ment with a power of at least 80%, even for risk factors with a
low prevalence of 5% in the total cohort. Depending on the
availability and quality of patient’s end-point data, or if the
prevalence of the primary outcome is less than 15%, it may be
necessary to recruit more or less participants into the study.
Recruitment and screening
Recruitment takes place at the research sites and health
care facilities through collaboration with National TB
Fig. 1 Screening algorithm
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Program (NTP), and in the communities which might be
enhanced by individual and community awareness through
advertisement, posters, radio announcements, and com-
munity sensitization campaigns. Each study site imple-
ments its own strategy to enhance recruitment.
Study procedures
Clinical and pulmonary assessments, biological sample
collections and collection of socio-economic data will be
performed according to the pre-defined SOE. All en-
rolled patients will be treated within the NTP and
Table 1 Schedule of Events (SOE)
Activities Screening Baseline Day 14 Month 2 Month 4 Month 6 Month 9 Month 12 Month 18 Month 24
Visits
Eligibility assessment x
Xpert MTB/RIF (Ultra) assay x
Sputum smear and culture x x x x x (x) (x) (x) (x)
Drug sensitivity testing x
Demographic data x
Clinical examination x x x x x x x x x
Chest X-ray x x x
Lung function assessment x x x x x x x
ECG x x x
Medical history (update) x x x x x x x x x
TB treatment and adherence x x x x (x) (x) (x) (x)
Quality of life/patient’s cost
questionnaire
x x x x x
HIV test (CD4 count) x x x
Hepatitis B serology x
Haematology and Biochemistry x x x x
Urine dip stick test x x x x
Blood storage for nested
research studies
x x x x x x x
Sputum storage for nested
research studies
x x x x x (x) (x) (x) (x)
Urine storage for nested
research studies
x x x x (x) (x) (x) (x)
Table 2 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
1 At least one sputum sample tested positive for MTB by Xpert MTB/RIF
assay in the study clinic/study laboratory or at least one sputum
sample tested positive by culture methods in study laboratory or
other TB laboratory
Anti-TB treatment in the last 6 monthsa
2 Be ≥18 years of age Incapacity to produce and provide two sputum samples
of sufficient volume and qualityb
3 Willing to provide a written consent or witnessed oral consent in the
case of illiteracy for participation in the study, prior to patient’s first
sample or other study-specific data being collected
Severe medical or psychiatric condition which in the opinion of the
site investigator or designee, might interfere with the ability to give
true informed consent and to adhere to the study requirements
4 Willing to be tested for HIV infection Currently imprisoned
5 Agreeing to the collection and storage of blood, urine, and
sputum specimens
Taking part in investigational product trials related to TB and/or
lung diseases
6 Willing to start anti-TB treatment after TB diagnosis
7 Living within the study area and willing to inform the study team
of any change of address during the treatment and follow up period
aTo ensure that no treatment failure are recruited into (immunological or genetic) marker studies
bTo ensure sufficient amount of sputum for host- and mycobacterial marker studies
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receive anti-TB treatment according to the local national
guidelines.
Clinical assessments and procedures
We will assess the pulmonary outcome, co-morbidities
and clinical risk factors using a number of methods.
These include: spirometry using the EasyOne or EasyOnPC
(ndd Medical Technologies, Inc., Zurich, Switzerland), Elec-
trocardiogram (ECG), 6min walking test (6MWT), chest
X-ray, St. George’s respiratory questionnaire, blood analysis
(haematology, biochemistry including HbA1c, HIV/CD4,
hepatitis B), urinalysis and risk-factors questionnaires (risk
behaviour, environmental and occupational risk factors,
among others). In addition, household air pollution is esti-
mated by measuring participant’s breath carbon monoxide
(CO) output (exhaled CO levels), which is collected using a
handheld breath CO monitor - The Micro+™ Smokerlyzer®
(Bedfont® Scientific Ltd., UK).
Laboratory procedures and testing
All laboratory procedures (apart from some specific as-
says planned for investigation of host-immune response
or pathogen characteristics not locally available) will be
performed at each study site and at the designated site
laboratories under the supervision of the study principal
investigators and using unified standard operating proce-
dures. In the study TB labs we will carry out standard
TB diagnostic procedures including smear, Xpert MTB/
RIF or Ultra assay (Cepheid Inc., USA), liquid and solid
culture, drug resistance testing in culture and molecular
speciation testing. For analysis of pathogen-related risk
factors, we will perform a number of pilot studies includ-
ing characterization of MTB strains by next generation
whole genome sequencing, identification of mixed infec-
tions and minority subpopulations as well as capture the
bacterial load, e.g. using molecular methods to monitor
treatment response. A number of different assays will be
performed to study in detail the host response to TB treat-
ment and individual predisposing risk factors for long
term lung outcome on stored samples, such as (but not
limited to) sputum and whole blood transcriptomics, flow
cytometry, cytokine assays and host-genetic analysis.
Assessments related to socio-economic consequences and
quality of life
All patients will be interviewed by trained study staff
using a novel version of the WHO’s generic TB patient
cost survey instrument [27] which has been adapted for
both the longitudinal study design and local context of
each setting. The instrument includes questions about
direct out-of-pocket costs (net of reimbursement) of
medical care, transport, food and accommodation during
health seeking, indirect costs such as income loss and
socio-economic coping mechanisms (e.g. taking a loan,
selling assets or property or taking children out of
school). Moreover, the instrument collects information
about health insurance coverage and reimbursements
and social welfare or paid sick leave received. A stan-
dardized short-form 36 item health survey (SF-36) com-
bined with a PIQ-6™ (4 items) will simultaneously
measure overall health, pain severity and the impact on
functional health and well-being. In addition to the
above we will also be using the Sheehan Disability scale
(5 items) to assess health status impairment associated
with TB and Kessler Psychological Distress scale (K10), a
10 item questionnaire, to measure distress based on
questions about anxiety and depressive symptoms. These
are all standardized validated questionnaires that have
been widely used in TB studies and are simple to admin-
ister and repeatable over time. The patient cost and
quality of life questionnaires will be completed at base-
line and at pre-defined visits (e.g. 2, 6, 12 and 24
months). Health system costs will be based on actual pa-
tient usage with unit costs assigned, but will be collected
later for the 24 month period. Resource utilization and
treatment outcomes will be collected using clinical re-
cords, health facilities records, price lists and reports.
Sample collection and storage
Blood, sputum and urine specimens are obtained from
each patient at different time points for analysis and
storage. The SOE is aligned with The RePORT Inter-
national cohort and other TB cohorts to enable future
research collaborations with other TB research consortia
and facilitate comparability of outcome data across dif-
ferent cohorts. The researchers who manage or have ac-
cess to human specimen data are legally and ethically
obliged to protect these data according to international
standards. Specific samples, e.g. TB strains, will be shipped
to collaborating institutions and stored in their laborator-
ies for further analysis.
Stored specimens will also be accessible for evaluation
of future emerging TB diagnostics, genetic markers and
biomarkers, provided informed consent and ethical ap-
proval for future use are available. For any additional in-
vestigations not explicitly mentioned in the original
study protocol, a request for study amendment will be
submitted to the relevant ethics committees.
Data management and statistical analysis
A study specific database has been developed using a
web-based Clinical Data Management System - Open
Clinica®, for data entry and data cleaning, supervised by
the lead data manager at LMU. All data collected at each
performed visit must be entered in the respective electronic
case report forms (eCRFs) provided in the data base.
The statistical analysis of this observational cohort
study will be exploratory and use descriptive as well as
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inferential statistical methods. The statistical analyses
will primarily be based on all enrolled patients with valid
data available. Preliminary data sets will be analysed along
the study in the frame of interim analyses, with the final
analysis being completed once the database is locked.
Study monitoring
Study activities related to data generation, recording and
management processes will be monitored on a regular
basis. Two external monitors from coordinating institu-
tions have been assigned to this task. These clinical
monitors will follow the study closely, visit the sites at
regular intervals and will be in contact by phone and
written communication, as required. In addition to close
supervision by the external monitors as well as by a local
supervisor, one internal clinical monitor is supervising
the procedures in the study clinics at each study site in
the context of a continuing clinical monitoring training
which includes workshops and distance learning mod-
ules. Additionally, an External Advisory Board consisting
of six representatives of NTPs, local and international
policy makers as well as relevant (clinical) scientists in
the field of TB research was created to regularly evaluate
the study activities and research progress as well as sup-
port the process in scientific decision making with
regards to the global TB research agenda.
Ethical considerations
This study is performed in accordance with the study
protocol, the Declaration of Helsinki (October 2013) and
the WHO Handbook for Good Clinical Research Prac-
tice (July 2002) as well as any other applicable national
and other regulatory guidelines. The protocol, Informed
Consent Form (ICF), eCRFs and other relevant study
documents were reviewed and approved by all respective
Ethical Committees at each study site and also at coord-
inating institutions. All participants sign an ICF prior to
enrolment in the study. For each enrolled subject, we
will assign a unique study identification number, which
will be used to identify the subject’s data and sample
within the project. The eCRFs and other study docu-
ments do not include any identifying information linked
to the study ID in order to maintain confidentiality for
all records and data of the participants.
Discussion
Current guidelines do not foresee specific monitoring or
treatment of pulmonary injury related to TB, nor has
disability due to long term loss of lung function or other
sequelae been included in current global estimates of the
total burden of disease. Social support for TB patients
rarely consider the period after cure has been declared.
As NTP in most countries do not follow up patients
after “cure”, the extent of the long-term complications
and their impact on individuals and households so far
remain unknown.
The present lack of knowledge regarding the patho-
genic mechanisms or clinical co-factors causing adverse
outcomes in TB hinders the development and evaluation
of interventions to reduce the overall TB disease burden
or costs related to TB. Additionally, the lack of current,
geographically relevant information about the economic
impact of TB and the likely costs to national health sys-
tems pose an obstacle to efficient resource allocation
both within TB programs and across competing health
and social care priorities. Studies, such as TB Sequel,
examining long term disability and associated risk fac-
tors, income loss, and treatment-related costs are crucial
to inform the policy changes needed to address poor
long-term TB outcome and catastrophic costs burden.
Compared to other TB cohort studies TB Sequel will fol-
low patients for at least 24 months which enables us to
report lung outcome when any impairment related to
TB disease has stabilized, thus when it can be assumed
to have become chronic. Likewise the characteristics of
ongoing socio-economic consequences and disease bur-
den can be studied in those patients with relevant
chronic lung or other TB related injury for at least 24
months. This allows for new estimates of TB disease
burden which go beyond microbiological cure. Due to
sample size and selection of different study sites across
Africa we will be able to describe the influence of im-
portant potential risk factors on lung outcome such as
infection with an MDR-TB strain, HIV-coinfection and
comorbidities like COPD and diabetes but also the rele-
vance of different genetic and socio-economic back-
ground. On the other hand, the follow-up of only 24
months precludes the investigation of interrelation of
pulmonary TB with pre-existing and especially newly de-
veloped comorbidities as well as the influence of TB on
long term survival and socio-economic status. Another
limitation of the study is that the investigators have no
influence on the composition of and adherence to
anti-TB (and anti-retroviral) treatment and individual
treatment regimens might have a different influence on
lung outcome. On each study visit, co-medication and
drug adherence are documented in order to enable
sub-group analyses as well as to control for it during
analysis of other risk factors for poor treatment out-
comes. Finally, the capacities for adequate treatment and
follow up for the majority of diagnosed comorbidities
are currently limited or even not available at most study
settings.
Thus, the TB Sequel Project is an integral part of an
overall strategy to fill a knowledge gap needed to im-
prove TB treatment and outcomes globally. It is an inter-
disciplinary project that combines multiple components:
research, capacity building and translation of evidence
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into policies. All research sites will receive training and
are included in capacity building activities (both in human
resources and infrastructure) which creates an enabling
environment for research and increases competencies in
diagnosis and management of TB and lung health with
direct benefit for future TB patients.
Dissemination of results
We anticipate that the results of this study will be relevant
to a broader research community, health care providers
and policy makers. Hence, we will disseminate the findings
of this study through different channels, such as TB Sequel
web page (www.tbsequel.org), scientific articles in inter-
national peer-reviewed journals, presentations at national
and international conferences, social media and policy
briefs. To further increase the impact of our findings, na-
tional and supra-national stakeholders and decision makers,
including the World Health Organization, were consulted
early in the study planning process and results will be
regularly shared with these institutions to inform future
treatment guidelines and national health policies. The dis-
semination of research results will be an integral part of the
TB Sequel project which also focuses on collaboration
strengthening through: developing new and intensifying
existing links between involved research institutions by in-
tegrating and harmonizing common activities to create an
enabling environment at African research institutions for
the exchange of knowledge; participation of local, regional
and international stakeholders in the project to facilitate
translation of evidence from the TB Sequel study into
policy and practice’ and finally, the collaboration with other
research networks such as PanACEA, The RePORT Inter-
national, German Center for Infection Research (DZIF)
projects and RESULTS Africa to ensure the relevance and
impact of TB Sequel research activities.
Additional files
Additional file 1: TB Sequel Project partners and research sites.
(DOCX 276 kb)
Additional file 2: Overview diagram depicting the interrelation of the
main TB-cohort and embedded sub-studies. (DOCX 91 kb)
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